Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Clinical trial NCT03345810 · COMPLETED

Trial details

NCT number: NCT03345810
Sponsor: AIO-Studien-gGmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Metastatic Lung Cancer Non Small Cell Lung Cancer Lung Adenocarcinoma Metastatic Large Cell Lung Carcinoma Metastatic

Start date: 2017-12-14
Primary completion: 2022-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.